Upcoming webinar: The genetics of congenital myopathies in French Canadians
The Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are pleased to invite you to a basic science webinar on July 7 at 5:00-6:30pm EST about the genetics of congenital myopathies in French Canadians. This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organisational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.
If you have any questions, please email
Register HERE
Topics and speakers:
Welcome and Introduction on Congenital Myopathies in Québec
Dr. Bernard Brais (NMD4C Investigator)
Next-Generation Sequencing Approaches for the Diagnosis of Muscle Diseases
Dr. Martine Tétreault
A Novel Recessive TNNT1 Congenital Core-Rod Myopathy in French Canadians
Dr. David Pellerin
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.